Evidence map›Paper›PMID 31645373›Full record

ArticleJournal of clinical microbiology2019

Genotyping of Mycobacterium tuberculosis Rifampin Resistance-Associated Mutations by Use of Data from Xpert MTB/RIF Ultra Enables Large-Scale Tuberculosis Molecular Epidemiology Studies.

Brian Weinrick

Abstract readComment
In one paragraph

Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Sentinel-Site-Based Surveillance ofAntibiotics (Basel, Switzerland) · 2025
    Article
  2. Identification ofBio-protocol · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Brian WeinrickTrudeau Institute, Saranac Lake, New York, USA bweinrick@trudeauinstitute.org.ORCID 0000-0003-0880-4487

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular epidemiology studies of tuberculosis have been empowered in recent years by the availability of whole-genome sequencing, which has allowed a new focus on the adaptive significance of drug resistance mutations. Genome sequencing technology remains expensive, however, limiting the potential for larger studies. Conversely, during this same time the GeneXpert molecular diagnostic method has been deployed globally and now serves as a cornerstone of tuberculosis diagnosis and drug sensitivity testing. In this issue, Y. Cao, H. Parmar, A. M. Simmons, D. Kale, et al. (J Clin Microbiol 57:e00907-19, 2019, https://doi.org/10.1128/JCM.00907-19) report the development of an algorithm that can use high-resolution melting temperature data generated in the course of analysis using the next-generation Xpert MTB/RIF Ultra assay to accurately genotype rifampin resistance-associated mutations. When paired with a system to aggregate data from diagnostic laboratories, this technique has the potential to enable studies on the global scale of the epidemiology of tuberculosis drug resistance.

Indexed as

Antibiotics, AntitubercularTuberculosisDrug Resistance, BacterialGenotypeHumansMolecular EpidemiologyMutationMycobacterium tuberculosisRifampinSensitivity and SpecificityTemperatureAntibiotics, AntitubercularRifampin

Identifiers

PMID31645373
PMCPMC6935915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.